Diane E. Bennett, Ricardo J. Camacho, Dan Otelea, Daniel R. Kuritzkes, Hervé Fleury, Mark Kiuchi, Walid Heneine, Rami Kantor, Michael R. Jordan, Jonathan M. Schapiro, Anne-Mieke Vandamme, Paul Sandstrom, Charles A. B. Boucher, David van de Vijver, Soo-Yon Rhee, Tommy F. Liu, Deenan Pillay, Robert W. Shafer

Programs that monitor local, national, and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines and provide feedback on the success of HIV-1 treatment and prevention programs. To accurately compare transmitted drug resistance rates across geographic regions and times, the World Health Organization has recommended the adoption of a consensus genotypic definition of transmitted HIV-1 drug resistance. In January 2007, we outlined criteria for developing a list of mutations for drug-resistance surveillance and compiled a list of 80 RT and protease mutations meeting these criteria (surveillance drug resistance mutations; SDRMs). Since January 2007, several new drugs have been approved and several new drug-resistance mutations have been identified. In this paper, we follow the same procedures described previously to develop an updated list of SDRMs that are likely to be useful for ongoing and future studies of transmitted drug resistance. The updated SDRM list has 93 mutations including 34 NRTI-resistance mutations at 15 RT positions, 19 NNRTI-resistance mutations at 10 RT positions, and 40 PI-resistance mutations at 18 protease positions.